肿瘤患者静脉血栓栓塞症的危险因素分析

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (583 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the risk factors of patients with venous thromboembolism (VTE) and malignant tumor in Liuzhou People’s Hospital (“our hospital” for short) and find out the risk factors, so as to establish the risk assessment model of VTE and prevent the occurrence of VTE. Methods One hundred and eight patients with malignant tumor and VTE hospitalized in our hospital from March 2018 to September 2019 were selected as VTE group, while 105 patients with simple malignant tumor hospitalized in the same period were selected as non VTE group. Clinical characteristics and hematological indexes of two groups were compared, and the risk factors of VTE were analyzed by multivariate regression analysis. Results There were significant differences in tumor type and radiotherapy between two groups (P < 0.05). There were significant differences in white blood cell count, hemoglobin, prothrombin time (PT) and D-dimer between two groups (P < 0.05). Multivariate regression analysis showed that radiotherapy (OR = 0.176, 95%CI:0.047-0.661), tumor progression (OR = 4.120, 95%CI:1.689-10.054), venous catheterization (OR = 0.308, 95%CI:0.124-0.764), PT > 12.8 s (OR = 12.998, 95%CI:1.507-112.086), D-dimer ≥ 1.44 μg/mL (OR = 1.251, 95%CI:1.091-1.435) were the independent influencing factors of VTE (P < 0.05). Conclusion Radiotherapy, PT > 12.8 s and D-dimer ≥ 1.44 μg/mL are independent risk factors for tumor VTE, but the effect of PT extension on VTE is excluded after analysis.

Key words： Malignant tumor Venous thromboembolism Radiation therapy D-dimer Score model

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XIE Ruijie CHEN Shipeng LI Junming LU Zhuoli CAO Lijuan LIU Daihua

Cite this article:

XIE Ruijie CHEN Shipeng LI Junming LU Zhuoli CAO Lijuan LIU Daihua. Analysis of risk factors for venous thromboembolism in tumor patients[J]. 中国医药导报, 2021, 18(5): 105-108.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2021/V18/I5/105

[1] 李辉，姜格宁，中国胸外科静脉血栓栓塞症研究协作组.胸部恶性肿瘤围术期静脉血栓栓塞症预防中国专家共识（2018版）[J].中国肺癌杂志，2018，21（10）：739-752.
[2] 马军，中国临床肿瘤学会肿瘤与血栓专家委员会.肿瘤相关静脉血栓栓塞症的预防与治疗中国专家指南（2015版）[J].中国肿瘤临床，2015，42（20）：979-991.
[3] Olaf M，Cooney R. Deep venous thrombosis [J]. Emerg Med Clin North Am，2017，35（4）：743-770.
[4] Wilbur J，Shian B. Deep venous thrombosis and pulmonary embolism：current therapy [J]. Am Fam Physician，2017， 95（5）：295-302.
[5] Farge D，Frere C，Connors JM，et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer [J]. Lancet Oncol，2019，20（10）：e566-e581.
[6] 中华医学会外科学分会血管外科学组.深静脉血栓形成的诊断和治疗指南（第三版）[J].中华普通外科杂志，2017， 9（4）：250-257.
[7] 马军，中国临床肿瘤学会肿瘤与血栓专家共识委员会.肿瘤相关静脉血栓栓塞症预防与治疗指南（2019版）[J].中国肿瘤临床，2019，46（13）：653-660.
[8] 中国健康促进基金会血栓与血管专项基金专家委员会，中华医学会呼吸病学分会肺栓塞与肺血管病学组，中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会.医院内静脉血栓栓塞症防治与管理建议[J].中华医学杂志，2018，98（18）：1383-1388.
[9] 门学千，李贺明，董茜，等.肿瘤内科住院患者静脉血栓危险因素分析及现有风险评估模型预测价值研究[J].中国实用内科杂志，2019，39（8）：694-697.
[10] 刘燕娥，顾阳春，易福梅，等.283例系统性治疗的肺癌患者静脉血栓栓塞症的危险因素分析[J].中国肺癌杂志，2019，22（7）：419-426.
[11] 王南南，陈冠男，余飞，等.肿瘤相关静脉血栓栓塞症预防和治疗的现状与挑战[J].现代肿瘤医学，2018，26（2）：310-314.
[12] Haltout J，Awada A，Paesmans M，et al. Predictive factors for cancer-associated thrombosis in a large retrospective single-center study [J]. Support Care Cancer，2019，27（4）：1163-1170.
[13] 热伊拉·麦买提伊敏，开丽曼·阿不都巴热，杨杰，等.宫颈癌根治性放疗后下肢深部静脉血栓形成的临床分析[J].现代肿瘤医学，2016，24（3）：454-457.
[14] Guy JB，Bertoletti L，Magné N，et al. Venous thromboembolism in radiation therapy cancer patients：findings from the RIETE registry [J]. Crit Rev Oncol Hematol，2017， 113：83-89.
[15] National Comprehensive Cancer Network. Cancer-associated venous thromboembolic disease [M]. Version 1. 2019.
[16] Nezi-Cahn S，Sicking I，Almstedt K，et al. Risk factors for chemotherapy-associated venous thromboses in gynaecological oncology patients [J]. Geburtshilfe Frauenheilkd，2019，79（10）：1100-1109.
[17] Reitter EM，Kaider A，Ay C，et al. Longitudinal analysis of hemostasis biomarkers in cancer patients during the anti-tumor treatment [J]. J Thromb Haemostas，2016，14（2）：294-305.
[18] Pabinger I，van Es N，Heinze G，et al. A clinical prediction model for cancer-associated venous thromboembolism：a development and validation study in two independent prospective cohorts [J]. Lancet Haematol，2018， 5（7）：e289-e298.
[19] Pabinger I，Thaler J，Ay C. Biomarkers for prediction of venous thromboembolism in cancer [J]. Blood，2013，122（12）：2011-2018.
[20] 崔婵娟，崔巍.关注肿瘤相关静脉血栓形成的风险预测[J].中华检验医学杂志，2019，42（4）：236-240.
[21] Haltout J，Awada A，Paesmans M，et al. Predictive factors for cancer-associated thrombosis in a large retrospective single-center study [J]. Support Care Cancer，2019，27（6）：1163-1170.
[22] 蒲纯，许小毛，乔力松，等.恶性肿瘤并发静脉血栓栓塞症的临床分析[J].中华老年多器官疾病杂志，2016，15（11）：810-814.
[23] Nair CK，Bhattacharjee A，Raghavan V，et al. Impact of thrombosis on standard treatment in solid tumors [J]. Thromb Res，2015，136（5）：943-946.
[24] Tan L，Sun Y，Zhu LL，et al. Risk factors of catheter-related thrombosis in early-stage breast cancer patients：a single-center retrospective study [J]. Cancer Manag Res，2019，11：8379-8389.
[25] Khorana AA，Francis CW. Risk prediction of cancer-associated thrombosis：appraising the first decade and developing the future [J]. Thromb Res，2018，164（Suppl 1）：S70-S76.